OBJECTIVE: The aim of this paper is to compare the costs of autologous bone marrow transplantation (ABMT) and whole blood transplantation in patients with relapsed or poorly responding non-Hodgkin's lymphoma. DESIGN AND SETTING: In a retrospective study, we calculated the treatment costs of 40 patients who received either ABMT or, alternatively, whole blood mobilised by filgrastim (a granulocyte colony-stimulating factor. MAIN OUTCOME MEASURES AND RESULTS: The recovery of granulocytes was markedly accelerated in the whole blood group as compared with the ABMT group. This resulted in a reduction in hospital costs, and costs for diagnostics and medical procedures, antibacterials, nutrition and blood transfusions. The average costs per patient in the whole blood group amounted to approximately $US16,890 as compared with approximately $US20,713 in the ABMT group (1995 values), implying a cost reduction of 18% when changing to whole blood reinfusion. CONCLUSIONS: With the premise that both therapies are equivalent, it seems that whole blood transplantation is more cost effective than ABMT.
OBJECTIVE: The aim of this paper is to compare the costs of autologous bone marrow transplantation (ABMT) and whole blood transplantation in patients with relapsed or poorly responding non-Hodgkin's lymphoma. DESIGN AND SETTING: In a retrospective study, we calculated the treatment costs of 40 patients who received either ABMT or, alternatively, whole blood mobilised by filgrastim (a granulocyte colony-stimulating factor. MAIN OUTCOME MEASURES AND RESULTS: The recovery of granulocytes was markedly accelerated in the whole blood group as compared with the ABMT group. This resulted in a reduction in hospital costs, and costs for diagnostics and medical procedures, antibacterials, nutrition and blood transfusions. The average costs per patient in the whole blood group amounted to approximately $US16,890 as compared with approximately $US20,713 in the ABMT group (1995 values), implying a cost reduction of 18% when changing to whole blood reinfusion. CONCLUSIONS: With the premise that both therapies are equivalent, it seems that whole blood transplantation is more cost effective than ABMT.
Authors: G J Ossenkoppele; A R Jonkhoff; P C Huijgens; J J Nauta; K G van der Hem; A M Dräger; M M Langenhuijsen Journal: Bone Marrow Transplant Date: 1994-01 Impact factor: 5.483
Authors: J M Vose; J O Armitage; P J Bierman; D D Weisenburger; M Hutchins; M D Dowling; D F Moravec; S Sorensen; J Okerbloom; G Bascom Journal: Am J Med Date: 1989-09 Impact factor: 4.965
Authors: G J Ossenkoppele; G J Schuurhuis; A R Jonkhoff; A M Dräger; G Westra; J W Oberink; M C Legdeur; A M de Kreuk; S Zweegman; P C Huijgens Journal: Bone Marrow Transplant Date: 1996-08 Impact factor: 5.483
Authors: D L Longo; V T DeVita; P L Duffey; M N Wesley; D C Ihde; S M Hubbard; M Gilliom; E S Jaffe; J Cossman; R I Fisher Journal: J Clin Oncol Date: 1991-01 Impact factor: 44.544
Authors: L F Verdonck; W L van Putten; A Hagenbeek; H C Schouten; P Sonneveld; G W van Imhoff; H C Kluin-Nelemans; J M Raemaekers; R H van Oers; H L Haak Journal: N Engl J Med Date: 1995-04-20 Impact factor: 91.245
Authors: C Faucher; A G le Corroller; D Blaise; G Novakovitch; P Manonni; J P Moatti; D Maraninchi Journal: Bone Marrow Transplant Date: 1994-12 Impact factor: 5.483